Takeda Pharmaceutical (TAK) Operating Leases (2020)
Takeda Pharmaceutical (TAK) posted quarterly Operating Leases of $601.4 million for Q3 2020.
Takeda Pharmaceutical (TAK) Operating Leases (2020) Analysis & Trends
Takeda Pharmaceutical's Operating Leases history runs 1 years deep, the most recent figure standing at $601.4 million for Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.64 Bn | 2.15 Bn |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.74 Bn | 22.95 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.26 Bn | 19.60 Bn | 683.80 Mn |
| 6 | Viatris | 18.85 Bn | 17.96 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.15 Bn | 11.62 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Alkermes | 8.28 Bn | 7.62 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 601.40 Mn |